Drug Type Small molecule drug |
Synonyms JP 1366, JP-1366, OCN-101 + [1] |
Target |
Action inhibitors |
Mechanism ATPase inhibitors(ATPase inhibitors), P-CAB(Potassium-competitive acid blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date South Korea (24 Apr 2024), |
Regulation- |
Molecular FormulaC28H34N4O8 |
InChIKeyLYCCRSPDKSGPRQ-UHFFFAOYSA-N |
CAS Registry2936619-43-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Erosive gastro-esophageal reflux disease | South Korea | 24 Apr 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Esophagitis, Peptic | NDA/BLA | China | 25 Aug 2025 | |
Peptic Ulcer Hemorrhage | Phase 3 | China | 27 Aug 2025 | |
Stomach Ulcer | Phase 3 | United States | 19 Sep 2022 | |
Erosive esophagitis | Phase 3 | United States | 17 Jan 2022 | |
Helicobacter-associated gastritis | Phase 1 | United States | 18 Nov 2020 | |
Ulcer | Phase 1 | United States | 22 Dec 2017 |
NCT05443984 (Pubmed) Manual | Phase 3 | 300 | zqgwedlgjn(hhwynwnodd) = tuqshrsnha dvnnnadypy (fmcfgjviei ) View more | Positive | 03 Jul 2024 | ||
zqgwedlgjn(hhwynwnodd) = rcwboilatg dvnnnadypy (fmcfgjviei ) View more | |||||||
Phase 3 | 300 | zastaprazan 20 mg | eyiweckosa(assnxzmhpp) = ynzfwjrpbk upxqwtuusd (fsvpgtuqyn ) View more | Non-inferior | 29 May 2024 | ||
埃索美拉唑 40 mg | eyiweckosa(assnxzmhpp) = kouxuhqjxz upxqwtuusd (fsvpgtuqyn ) View more | ||||||
Pubmed Manual | Clinical | - | Zastaprazan 20mg | arewugnbqw(bddepkaxim) = fsysvrhpge uhfctjcgvq (hloauiktyc ) | Positive | 02 Feb 2023 | |
Zastaprazan 40mg | arewugnbqw(bddepkaxim) = hbrqiowgkx uhfctjcgvq (hloauiktyc ) |